<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Reactive oxygen species (ROS) derived from Nox2-containing reduced form of <z:chebi fb="0" ids="25523">nicotinamide adenine dinucleotide phosphate</z:chebi> (<z:chebi fb="1" ids="16474">NADPH</z:chebi>) oxidase activity is reportedly detrimental in cerebrovascular disease </plain></SENT>
<SENT sid="1" pm="."><plain>However, ROS generation by other Nox isoforms may have a physiological role </plain></SENT>
<SENT sid="2" pm="."><plain>No Nox2-selective inhibitors have yet been identified, and thus it is unclear whether isoform non-selective Nox inhibitors would necessarily improve outcome after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed the effect of <z:chebi fb="0" ids="2781">apocynin</z:chebi> on cerebrovascular ROS production and also on outcome following <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> when administered either before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> or after cerebral reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>The involvement of Nox2-containing <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase in the effects of <z:chebi fb="0" ids="2781">apocynin</z:chebi> was assessed using Nox2(-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>EXPERIMENTAL APPROACH: <z:e sem="disease" ids="C0917805,C0007787" disease_type="Disease or Syndrome" abbrv="">Transient cerebral ischaemia</z:e> was induced by 0.5 h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 23.5 h reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Mice received <z:chebi fb="0" ids="2781">apocynin</z:chebi> (2.5 mg.kg(-1), i.p.) either 0.5 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> or 1 h after reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>In situ <z:chebi fb="1" ids="18421">superoxide</z:chebi> production after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>-reperfusion was measured in brain sections of <z:mp ids='MP_0002169'>wild-type</z:mp> mice at 24 h using dihydroethidium fluorescence </plain></SENT>
<SENT sid="8" pm="."><plain>KEY RESULTS: Treatment with <z:chebi fb="0" ids="2781">apocynin</z:chebi> 0.5 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> reduced total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological impairment and mortality in <z:mp ids='MP_0002169'>wild-type</z:mp> but not Nox2(-/-) mice </plain></SENT>
<SENT sid="9" pm="."><plain>Conversely, treatment with <z:chebi fb="0" ids="2781">apocynin</z:chebi> 1 h after initiation of reperfusion had no protective effect </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">Cerebral ischaemia</z:e> and reperfusion increased <z:chebi fb="1" ids="18421">superoxide</z:chebi> production in the brain at 24 h, and pretreatment but not posttreatment with <z:chebi fb="0" ids="2781">apocynin</z:chebi> reduced <z:chebi fb="1" ids="18421">superoxide</z:chebi> levels </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS AND IMPLICATIONS: <z:chebi fb="0" ids="2781">Apocynin</z:chebi> improves outcome following <z:hpo ids='HP_0001297'>stroke</z:hpo> when administered before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in <z:mp ids='MP_0002169'>wild-type</z:mp> but not Nox2(-/-) mice </plain></SENT>
</text></document>